The digital IND/NDA/BLA is an innovative conceptual framework for regulatory applications that leverage in silico modeling using artificial intelligence, machine learning, and neural network technologies. These frameworks establish fully digital submission pathways where nonclinical simulation (no animal testing), in silico clinical pharmacology, clinical study modeling, and the creation of regulatory data and documents through submission are conducted in AI applications with expert human supervision. This article will examine generative artificial intelligence (gen AI) in producing regulatory documents, looking at time savings, current vendors, writing and editing style, the impact of company size, and augmentation. It also addresses vendor evaluation and cost/return on investment considerations. Keywords – biologics license application, digital submission, generative AI, investigational new drug, in silico, human supervision, new drug application